Press Room

    Back

    Press Release - August 06, 2009

    Appointment of Dr. Annemarie Moseley to the Sernova Business Advisory Board


    London, Ontario -- August 6, 2009 - Sernova Corp. (TSX-V: SVA)

    Dr. George Adams, Chairman of the Board of Directors and Dr. Philip Toleikis, President and CEO of Sernova Corp. are pleased to announce the appointment of Dr. Annemarie Moseley to the Corporation's Business Advisory Board.

    In reference to the appointment, Dr. Adams said "I am pleased to welcome Dr. Moseley to the Sernova team. She brings a wealth of technical and business experience in the cell therapy arena that will be of significant benefit to our company."

    Dr. Toleikis said "Dr. Moseley's depth of experience in cell-based product development, clinical and regulatory affairs as well as financing and partnering will be a great asset from a strategic perspective. We anticipate that she will play a key supportive role as we advance our cell therapy programs toward commercialization and consider partnering opportunities. On behalf of the Corporation's shareholders and the other Board members, I am pleased to welcome her to Sernova's Business Advisory Board."

    Dr. Moseley earned a Ph.D. in Physiology and Biochemistry from Utah State University, and an M.D. from Baylor College of Medicine. Her corporate career began as Vice President, Clinical Research for Applied Immune Sciences from 1992 to 1995, overseeing clinical development of stem cell therapies for HIV, bone marrow transplantation and gene therapy. Subsequently, in her role as Director of Clinical Gene Therapy at SyStemix/Novartis, Dr. Moseley managed a stem cell- based HIV gene therapy program. In 1997, Dr. Moseley joined Osiris Therapeutics as Senior Vice President of Clinical and Regulatory affairs, leading development activities for mesenchymal stem cell-based products in oncology, orthopaedics, cardiovascular and lysosomal storage disorders. Later as President, CEO and a Director of Osiris Therapeutics, Inc., she participated in extensive fundraising and partnering activities. In 2002 Dr. Moseley founded Cognate Therapeutics, Inc. with Toucan Capital and as President and CEO led the development of a cellular therapy for glioblastoma. She has acted as a strategic consultant on cellular therapies to a number of medical device companies and as commercialization advisor to the Canadian Stem Cell Network. Dr. Moseley is currently Chairman and CEO of REPAIR Technologies, Inc., a startup biotech company focused on enhancing repair and regeneration of injured tissue.

    About Sernova

    Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(tm) and its patented Sertolin(tm) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

    This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

    For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

    THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

    Back



    Press Releases from:

    2017 2016 2015 2014 2013 2012 2011

    2010 2009 2008 2007 2006 2005 2004

    2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs

    Link

    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance

    PDF

    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario

    Link

    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Publisher: StockInterview.com
    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Publisher: StockInterview.com
    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Publisher: StockInterview.com
    Author: James Finch

    Presentation and Video

    September 11, 2017

    Sernova Fact Sheet

    September 11, 2017

    Sernova's 2017 Corporate Presentation

    PDF Presentation

    Subscribe to Sernova News

Subscribe to our News Dispatch Service

* indicates required




Latest Video and Presentation


Sernova Fact Sheet - / September 11, 2017 Open


Sernova's 2017 Corporate Presentation - PDF Presentation / September 11, 2017 Open

All Presentations →